Today, the Chairman, President and CEO of Omnicell (OMCL), Randall Lipps, sold shares of OMCL for $1.71M.
Following Randall Lipps’ last OMCL Sell transaction on June 20, 2018, the stock climbed by 33.1%. In addition to Randall Lipps, 2 other OMCL executives reported Sell trades in the last month.
See today’s analyst top recommended stocks >>
Based on Omnicell’s latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $212 million and quarterly net profit of $14.79 million. In comparison, last year the company earned revenue of $198 million and had a net profit of $24.29 million. OMCL’s market cap is $3.37B and the company has a P/E ratio of 93.33. Currently, Omnicell has an average volume of 273.2K.
One of the top 25 analysts, according to TipRanks.com, recently recommended Buy OMCL with a $80 price target. Based on 3 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $78.67, reflecting a -8.7% downside.
The insider sentiment on Omnicell has been negative according to 79 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Randall Lipps’ trades have generated a -3.1% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Omnicell, Inc. engages in the provision of automation and business analytics software solutions for patient-centric medication and supply management. It operates through Automation and Analytics, and Medication Adherence segments.